Overview

* Acumen Q3 net income and income from operations beat analyst estimates

* Company's cash expected to support operations into early 2027

* R&D expenses decreased due to reduced CRO costs for ALTITUDE-AD trial

Outlook

* Company expects topline results from ALTITUDE-AD study in late 2026

* Company anticipates non-clinical data to inform EBD strategy in early 2026

* Cash reserves expected to support operations into early 2027

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses attributed to reduced CRO costs for ALTITUDE-AD trial

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat -$26.45 -$35.46

Income mln mln (4

Analysts

)

Q3 Beat -$26.51 -$33.83

Income mln mln (4

From Analysts

Operatio )

ns

Q3 Basic -$0.44

EPS

Q3 $26.51

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc ( ABOS ) is $9.50, about 79.3% above its November 11 closing price of $1.97

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)